Physician profile
John C Henry
NPI 1740205822
$1,288.02
in general payments reported to CMS, 2019-2025
22 companies · $91.73 in 2025
The $91.73 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $94.01 · 2021: $187 · 2022: $53.64 · 2023: $234 · 2024: $248 · 2025: $91.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.58 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $165.97 | 2019-2020 | |
| Amgen INC. | $164.18 | 2019 | |
| Abbvie INC. | $147.61 | 2023-2025 | |
| Medtronic, INC. | $122.33 | 2023-2024 | Percept Pc Brainsense |
| Sunovion Pharmaceuticals INC. | $91.94 | 2019-2021 | |
| Livanova USA, INC. | $72.24 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbott Laboratories | $64.18 | 2021 | |
| Inspire Medical Systems, INC. | $53.73 | 2023-2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $47.28 | 2021-2022 | |
| Pfizer INC. | $46.76 | 2021-2023 | |
| Catalyst Pharmaceuticals, INC. | $44.31 | 2019-2024 | |
| Genzyme Corporation | $43.08 | 2019-2022 | |
| Ge Healthcare | $39.65 | 2025 | |
| Neurocrine Biosciences, INC. | $24.65 | 2023 | Ongentys, Ingrezza |
| Nevro Corp. | $22.11 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $21.96 | 2023 | Epidiolex |
| Sumitomo Pharma America, INC. | $21.79 | 2023 | Aptiom |
| Celgene Corporation | $21.75 | 2024 | Zeposia |
| Aquestive Therapeutics, INC. | $21.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.05 | 2021 | |
| Allergan, INC. | $19.54 | 2021 | |
| Currax Pharmaceuticals LLC | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.